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Abstract 
 
Throughout their entire life cycle, mRNAs are associated with RNA-binding proteins (RBPs), forming 
ribonucleoprotein (RNP) complexes with highly dynamic compositions. Their interplay is one key to 
control gene regulatory mechanisms from mRNA synthesis to decay. To assay the global scope of RNA-
protein interactions, we and others have published a method combining crosslinking with highly 
stringent oligo(dT) affinity purification to enrich proteins associated with polyadenylated RNA (poly(A)+ 
RNA). Identification of the poly(A)+ RNA-bound proteome (also: mRNA interactome capture) has by now 
been applied to a diversity of cell lines and model organisms, uncovering comprehensive repertoires of 
RBPs and hundreds of novel RBP candidates. In addition to determining the RBP catalog in a given 
biological system, mRNA interactome capture allows the examination of changes in protein-mRNA 
interactions in response to internal and external stimuli, altered cellular programs and disease.  
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1. Introduction 
 
Almost all classes of RNAs are subject to intricate post-transcriptional regulatory control coordinating 
their maturation, transport, stability and degradation [1]. RNA-binding proteins (RBPs) engage with 
RNAs to form higher-order ribonucleoprotein (RNP) complexes and act synergistically in order to shape 
RNA fate [2-5]. The dynamic compositions of RNP complexes provide not only specificity to regulatory 
processes, but also make post-transcriptional regulation highly responsive to external cues by 
remodeling of RNP complexes. Thus, regulatory modes are dependent on the abundance of RBPs and 
the competition between RBPs with overlapping target specificity which facilitates interrogation of 
posttranscriptional networks by profiling RBPs globally. We and others published the first 
comprehensive mRNA-binding protein repertoires in mammalian cells by applying a method termed 
mRNA interactome capture [6, 7]. By now, this approach has been successfully applied to cell lines such 
as HEK293 [6], HeLa [7], Huh-7 [8], mESC [9], RAW 264.7 [10], HL-1 [11] as well as a diverse set of 
organisms including Saccharomyces cerevisiae [8, 12], Caenorhabditis elegans [12], Drosophila 
melanogaster [13, 14], Arabidopsis thaliana [15, 16], Plasmodium falciparum [17], Leishmania donovani 
[18] and Danio rerio [19] . 
 
mRNA interactome capture can be characterized by two features: The formation of covalent bonds 
between RNAs and proteins induced in vivo by UV crosslinking as well as the highly stable bead-coupled 
oligo(dT)-poly(A) tail hybridization and affinity purification for mRNA enrichment. The combination of 
both elements allows for stringent purification of poly(A)+ RNA associated protein factors by using 
elevated amounts of chaotropic agents to eliminate unspecific interactions in otherwise highly complex 
mixtures (such as concentrated cell extracts). 
 
Similar to crosslinking and immunoprecipitation (CLIP) methods [20-23], covalent bond formation 
between proteins and RNA is achieved by UV crosslinking, a photo-crosslinking approach for which 
monochromatic UV light irradiation is used. It induces short-lived free radicals at nucleotide bases 
resulting in covalent bond formation with amino acids of proteins in direct vicinity (~2 Å, “zero 
distance”) [24, 25]. Two approaches are commonly used fur UV crosslinking: Conventional UV 
crosslinking (cCL) uses UV irradiation at 254 nm wavelength to induce covalent bond formation between 
nucleic acids and proteins. Alternatively, incorporation of photoactivatable ribonucleosides (PARs) such 
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as 4-thiouridine (4SU) and 6-thioguanosine (6SG) into newly synthesized RNAs to enhance crosslinking 
(PAR-CL) can be utilized [26]. In this case, UV irradiation at lower-energy 365 nm wavelength initiates 
covalent bond formations between RNAs and proteins at sites of 4SU and 6SG incorporation.  
 
Despite being the crosslinking approach of choice in combination with mRNA interactome capture, UV 
irradiation might not always be a feasible choice as light penetration (cCL and PAR-CL) or nucleoside 
incorporation (PAR-CL) can limit the efficacy of the procedure. For instance, applying UV crosslinking to 
non-etiolated plants could further reduce efficacy of the approach due to the presence of UV light-
absorbing chloroplasts. For organisms that are not transluscent, UV crosslinking could only be 
successfully applied with extended crosslinking periods [8, 27]. To overcome this limitation, chemical 
crosslinking using formaldehyde (FA) could be used to covalently crosslink RNA and interacting proteins 
in a similar fashion as in the RIPiT-seq protocol [28]. Of note, FA crosslinking also induces covalent bond 
formation between proteins, a feature which can be exploited to stabilize higher-order RNPs. 
 
Here, we provide a protocol suitable for usage with mammalian cell culture systems and show that 
modifications to the protocol, e.g. the crosslinking approach, can be made. Moreover, we discuss the 
advantages and shortcomings of the hallmarks of this protocol – crosslinking and oligo(dT) affinity 
purification – in more detail. 
 
2. Method 
2.1. mRNA interactome capture in mammalian cells 
 
As a quick reference guide, we included a step-by-step protocol and troubleshooting section in the 
Supplemental material which can be used for the bench work.  
 
2.1.1. Cell Culture and crosslinking 
 
Cells are grown in appropriate growth medium and expanded to tissue culture plates with a diameter of 
150 mm. Dependent on the cellular system of choice, ~107-108 cells per sample will be subjected to one 
out of three crosslinking procedures (a-c). (a) For conventional UV crosslinking (cCL), the culture medium 
is removed and plates are directly transferred onto ice. Cells are crosslinked with 254 nm UV light (0.15 
J/cm2) on ice using a Stratalinker 2400 (Stratagene). (b) For photoactivatable-ribonucleoside-enhanced 
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crosslinking (PAR-CL), the cell culture growth medium of cells at 70-80% confluency is supplemented 
with 4SU for not more than 8 hours of metabolic labeling. We suggest starting with a final concentration 
of 100 µM or 200 µM 4sU which usually yields good incorporation results while maintaining effects of 
cellular stress at a minimum [37]. For short labeling times (1-2 hours) higher 4SU concentrations of 600 -
800 mM final concentration can be used. As 4SU incorporation rates into nascent RNA can greatly vary 
between cellular systems, it is recommended to test labeling efficiencies beforehand. Usually, we use 
comparison to 4SU incorporation rates observed in HEK293 cells by thiol-specific biotinylation [29] or LC-
MS analysis [30]. Of note, global characterization of the RBP repertoire in HEK293 cells can be achieved 
with 4SU incorporation efficiencies between 1% and 4% [6, 26]. After metabolic labeling, the cell culture 
growth medium is removed and plates are transferred onto ice. Cells are crosslinked with 365 nm UV 
light (0.15-0.2 J/cm2) on ice using a Stratalinker 2400 (Stratagene). (c) For formaldehyde (FA) 
crosslinking, culture medium is removed and 10 ml of 0.05% to 0.1% formaldehyde solution (in PBS) per 
plate are added. At room temperature, the plates are gently rocked for 10 minutes and crosslinking is 
quenched by the addition of 2 ml 1.5M glycine per plate. The plates are rocked for another 5 minutes, 
aspirated and transferred onto ice. Importantly, we want to point out that the FA crosslinking procedure 
should be optimized individually for any given cellular system beforehand using the detection of known 
RBPs by Western analysis as a benchmark (see 2.2.3.). In particular, elevated FA concentrations and 
excessive incubation times favor accumulation of crosslinking of non-native interaction events which 
should be minimized. (a-c) 3 ml of ice-cold PBS per plate are added, cells are scraped off with a rubber 
policeman and collected in a pre-cooled falcon by centrifugation. Cell pellets are washed at least once in 
ice-cold PBS followed by centrifugation and flash-freezing in liquid nitrogen for long-term storage 
(alternatively, proceed to section 2.1.2 immediately).   
 
2.1.2. Preparation of cell lysate and oligo(dT) pulldown 
 
Cell pellets are lysed in 10 pellet volumes of lysis/binding buffer (100 mM Tris-HCl, pH 7.5 at 25°C, 500 
mM LiCl, 10 mM EDTA, pH 8.0 at 25°C, 1% LiDS, add freshly: 5 mM DTT, Mini EDTA-free protease 
inhibitor (Roche)) by gentle pipetting until being fully resuspended. Following an incubation time of 15 
minutes at room temperature, further homogenization and genomic DNA shearing are achieved by 
passing the lysate 10 times through a 21 gauge needle and once through a 26 gauge needle. At times, 
lysates may turn out to be viscous, pointing towards a suboptimal ratio of cell material to lysis/binding 
buffer. In order to not affect the oligo(dT) pulldown, it is recommended to adjust the amount of 
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lysis/binding buffer accordingly. The Dynabeads mRNA DIRECT oligo(dT) beads (Thermo Fisher Scientific) 
are washed once in one original suspension volume of lysis/binding buffer. Typically, an equivalent of 2 
ml Dynabead suspension (bed volume: ~15 µl), as provided by the manufacturer, is used for a lysate of 
108 cells. After adding the oligo(dT) beads, lysates are incubated for 1 hour at room temperature on a 
rotating wheel. While RNA is usually processed at low temperatures in order to preserve its integrity, we 
do not recommend lowering the incubation temperature to avoid precipitation of LiDS which may 
impede binding of the oligo(dT) beads to RNA. Subsequently, the oligo(dT) beads are concentrated on a 
magnetic rack, lysates are transferred into new tubes and stored on ice for multiple rounds of oligo(dT) 
pulldown. Beads are washed three times in one lysate volume of lysis/binding buffer containing 1% of 
lithium dodecyl sulfate (LiDS). While the LiDS concentration in the lysis/binding buffer may be decreased 
in order to improve overall yield of the affinity purification, it is not recommended, as it would be at the 
expense of stringency and likely specificity of the poly(A)+ RNA-bound protein enrichment. Further three 
rounds of washes are performed in one lysate volume of NP40 Washing buffer (50 mM Tris-HCl, pH 7.5 
at 25°C, 140 mM LiCl, 2 mM EDTA, pH 8.0 at 25°C, 0.5% NP-40, add freshly: 0.5 mM DTT, Mini EDTA-free 
protease inhibitor (Roche)) followed by heat elution (80°C, 2 min) of crosslinked poly(A)+ RNA-protein 
complexes in 300 µl low-salt elution buffer. Before resuspending the oligo(dT) beads in the low-salt 
elution buffer, it is highly recommended to ensure full removal of leftover NP40 Washing buffer. 
Carryover of detergents may cause issues for downstream mass spectrometry applications. 
Implementation of one additional round of washing in one lysate volume of detergent-free washing 
buffer (50 mM Tris-HCl, pH 7.5 at 25°C, 140 mM LiCl, 2 mM EDTA, pH 8.0 at 25°C, add freshly: 0.5 mM 
DTT, Mini EDTA-free protease inhibitor (Roche)) may solve detergent-related problems. While the eluate 
is stored on ice, the oligo(dT) beads are re-incubated with the lysate for a total of three rounds of 
oligo(dT) hybridization by repeating the described procedure. Eluates are combined and stored at -80°C 
(alternatively, proceed to section 2.1.3). 
 
2.2. Downstream applications 
 
Eluates from the oligo(dT) enrichment protocol described in section 2.1 consist of crosslinked proteins 
(RBPs), crosslinked poly(A)+ RNA and non-crosslinked poly(A)+ RNA. 
 
2.2.1. RNase treatment  
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Following oligo(dT) affinity purification of crosslinked poly(A)+ RNA-protein complexes, proteins are 
released by RNA digestion in order to allow for further analysis. Incubating the eluate with RNase I (and 
optionally: Benzonase) at a final concentration of 0.1 U/µl in the presence of 1mM MgCl2 for a minimum 
of one hour at 37 °C is sufficient to fully recover the proteins. At this point, proteins can be directly 
subjected to mass spectrometry sample preparation. 
 
2.2.2. Protein quality control: SDS-PAGE 
 
To control for efficient enrichment of poly(A)+ RNA-bound proteins in the oligo(dT) eluate, 5% of the 
total eluate are used for analysis by SDS-PAGE. Figure 2 shows a representative silver stained SDS-PAGE 
gel for all three discussed crosslinking approaches. For all crosslinked and oligo(dT) affinity purified 
samples, characteristic patterns of protein bands distinct from the input control are visible. More so, our 
stringent oligo(dT) affinity purification protocol described here clearly supports enrichment of specific 
poly(A)+ RNA by oligo(dT) hybridization over unspecific interactions as in the non-crosslinked controls. 
We would like to note that in order to reduce background of the oligo(dT) pulldown to a minimum, 
proper resuspension of the beads during each round of washing is mandatory. Further reduction of 
background may be achieved by prolonged washing phases (one to three minutes on a rotating wheel at 
room temperature). Another factor subject to optimization is the amount of oligo(dT) beads used per 
sample. Preliminary calculations on total RNA yield per sample and small scale oligo(dT) pulldowns may 
indicate if the amount of beads used should be maintained or decreased according to the oligo(dT) 
beads binding capacity (as provided by the manufacturer). We strongly suggest to not deliberately use 
an excess of beads as this may increase the amount of co-purifying contaminants, and therefore 
background. The number of oligo(dT) affinity purification rounds should not be altered. In our previous 
work, we found that while multiple rounds of oligo(dT) pulldown may be beneficial to capture lowly 
abundant transcripts as well as transcripts with shorter poly(A) tails, further rounds of hybridization 
increase the amount of co-purifying contaminating RNA species such as ribosomal RNAs. With three 
rounds of oligo(dT) affinity purification, we were able to deplete 80% to 90% of mRNAs in cell lysates [6]. 
 
2.2.3. Protein quality control: Western analysis 
 
While running a SDS-PAGE sheds light onto how technical aspects of the mRNA interactome protocol 
worked, it does not reveal if the enrichment is specific for RBPs. A straightforward way to explore mRNA 
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interactome samples for specific enrichment of RBPs is to run a Western Blot. In the interest of 
monitoring RBP enrichment and non-RBP depletion, we suggest to save a small fraction of the input 
lysate (0.1% is sufficient) when performing the mRNA interactome protocol to assay with the eluate. 
Alongside your protein(s) of interest, we recommend adding a positive control (e.g. any of the hnRNP 
proteins – should be enriched in the eluate) and a negative control (e.g. tubulin – should be depleted in 
the eluate). 
 
2.2.4. poly(A)+ depletion control 
 
To measure the degree of poly(A)+ RNA depletion when applying the mRNA interactome protocol, 
quantitative Real-Time PCR (qRT-PCR) can be performed. The mRNA content after each round of 
oligo(dT) affinity purification as compared to the input can be estimated by assaying highly abundant 
transcripts of genes like GAPDH, TUBB or ACTA1/ACTB (positive control, polyadenylated) and compared 
to 18s rRNA (negative control, not polyadenylated) [6].  
 
2.2.5. Mass Spectrometry 
 
Proteome-wide detection of enriched RBPs can be achieved with mass spectrometry. Therefore, eluates 
from the mRNA interactome capture protocol need to be further processed. In short, eluates are 
subjected to TCA precipitation and resuspended in 8M Urea solution to concentrate and denature 
proteins. Disulfide bonds are reduced by adding dithiothreitol (DTT), followed by alkylation of sulfhydryl 
groups from cysteins with iodoacetamide (IAA) to irreversibly prevent reformation of disulfide bonds. 
Proteins are separated by SDS-PAGE and proteins are in-gel digested with Lys-C and trypsin. Resulting 
peptides are further concentrated and desalted with C18 column purification, strong cation exchange 
chromatography columns (SCX) and a second round of C18 column purification. The final peptide 
mixture can be measured with Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). 
Identification of proteins/peptides can be performed using MaxQuant [38]. 
 
2.3. Identification of RBPs in mRNA interactome capture mass spectrometry data 
 
We commonly use the label-free quantification (LFQ) approach as a relative quantification method for 
proteins across replicates and samples [39]. To apply statistical analysis, mean log fold-changes of 
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proteins identified in crosslinked samples over non-crosslinked control across replicates are generated 
using intensities. At this point, proteins with fold-changes that equal 0 (not enriched in crosslinked 
sample over non-crosslinked control) or smaller 0 (enriched in the non-crosslinked control over the 
crosslinked sample) are likely to be unspecifically co-purified during the mRNA interactome capture 
protocol. Next, significance for differential enrichment can be inferred using a t-test or empirical Bayes 
moderated t-test. Calculated p-values are not sufficient for proper interpretation of mRNA interactome 
capture data: As we are handling high dimensional data involving proteins with different abundance 
levels, RNA-binding modes and crosslinking probabilities which can influence identification and 
quantification of recovered proteins, multiple testing has to be performed to estimate the false 
discovery rate (FDR). By applying the Benjamini and Hochberg method and choosing a cutoff for the FDR 
(e.g. < 0.01), p-values will be adjusted accordingly (hence: p adj). Proteins which are not enriched or 
enriched with a FDR above 0.01 can be discarded from further analysis and are not identified as RBPs in 
this experimental setup. All other proteins which are enriched with a FDR below 0.01 are identified as 
RBPs by mRNA interactome capture, but by setting the FDR threshold to 0.01, we accept that 1% of 
those proteins are false positives. 
 
3. Discussion 
3.1. RNA-protein crosslinking 
 
UV crosslinking is the approach of choice for stabilization of RNA-protein interactions by covalent bond 
formation in our mRNA interactome protocol. Still, application of UV irradiation has its shortcomings. As 
shortly mentioned before, it is not applicable across biological systems with the same crosslinking 
efficacy. In general, the occurrence of crosslinking events is inherently low and taken together, both 
factors may impair successful stabilization of RNA-protein interactions. Another aspect that should be 
taken into consideration is that UV crosslinking is not unbiased. For cCL, potentially all four 
ribonucleosides can form photoadducts, but pyrimidines are more efficient crosslinking bases than 
purines [24]. In regards of PAR-CL, short labeling pulses with 4SU or 6SG can be utilized to increase 
crosslinking efficiency for certain RBPs [7]. On the other hand, RNA-protein interactions on uridine- or 
guanosine-poor transcripts might be underrepresented and not fully retrieved. Even for RBPs that can 
be readily UV crosslinked, differences between the cCL and the PAR-CL approaches can be observed that 
arise from the transcript sequence itself [7]. FA crosslinking might avoid these nucleotide composition-
dependent pitfalls. The underlying chemical crosslinking reaction consists of two consecutive 
  
10 
 
nucleophilic additions which crosslinks any biomolecule with another if both contain nucleophilic 
moieties and are proximal. In contrast to UV crosslinking which retrieves direct RNA-protein interactions 
exclusively, FA induced crosslinking enables stabilization of indirect RNA-binding factors as constituents 
of higher-order RNPs [28]. Here, we only provide a proof-of-principle showing that FA crosslinking can 
be combined with the mRNA interactome capture affinity purification protocol (Fig. 2). The crosslinking 
procedure itself should be further optimized to avoid false positive crosslinking events in order to 
maximize the yield of true interactions. 
 
3.2. oligo(dT) affinity purification 
 
mRNA interactome capture is a protocol to enrich mRNAs and their crosslinked adducts on a global 
scale. It exploits the presence of 3’ polyadenylation which is a common feature of mRNAs. mRNA should 
be captured from the moment the poly(A) tail is added until the removeal of the tail and mRNA decay. 
Since introns can be spliced posttranscriptionally or are tained [40], RBPs bound to these introns are 
likely identified by mRNA interactome capture. Unlike most mRNAs, histone mRNAs are not 
polyadenylated [33] and therefore not captured with our protocol. For polyadenylated mRNAs, the 
length of their poly(A) tails can vary greatly [33-35]. While there is still ongoing debate about the true 
range of poly(A) tail lengths [33], we do not expect the length of poly(A) tails to influence enrichment 
with our mRNA interactome capture protocol for most parts. It is a possibility that poly(A) tails shorter 
than 20 nucleotides might not be as efficiently captured as transcripts with longer poly(A) tails as the 
poly(A)-oligo(dT) hybridization becomes increasingly less stable.     
  
Besides, mRNA interactome capture does not only enrich mRNAs. lncRNAs are transcribed in a RNA 
polymerase II-dependent manner and many are polyadenylated [36], which impedes biochemical 
discrimination between mRNAs and lncRNA in our protocol. Therefore, a small subset of interacting 
proteins captured in our protocol can most likely be contributed to protein-lncRNA interaction.  
 
 
4. Concluding remarks 
Here, we provide a detailed protocol for mRNA interactome capture to enrich RBPs bound and 
crosslinked to poly(A)+ RNA. While single aspects of this protocol may be altered according to the 
experimenters needs and the biological system of interest, the overall framework is robust and highly 
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reproducible. One central future task is to expand the applicability of the approach to non-
polyadenylated RNAs to provide a more complete snapshot of the RBP repertoire.  More importantly, 
RNA interactome capture could be applied for comparative studies. Different RBPs within a single 
biological sample should not be compared as crosslinking biases will lead to misleading interpretations. 
In contrast, quantifying the enrichment of individual RBPs across different biological samples will give 
valuable insights into how the interactions of proteins with RNA are altered on a global scale, providing 
cues as to how dynamic protein-mRNA interactions are leading to plastic post-transcriptional regulatory 
mechanisms.     
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Figure Legends 
Fig. 1 – Detailed graphical representation of the mRNA interactome capture protocol for mammalian cell 
culture systems. Cells are crosslinked ( a. cCL, b. PAR-CL, c. FA) and lysed, then cell extracts are subjected 
to three consecutive rounds of oligo(dT) affinity purification. After each round, poly(A)+ RNA is collected 
by heat elution. Eluates are subjected to nuclease treatment for RNA removal. 
 
Fig. 2 – Quality control and analysis of oligo(dT) eluates by SDS-PAGE and silver stain. Shown from left to 
right are input (I), RNase control (R) and the oligo(dT) eluates from cCL, PAR-CL and FA-crosslinked 
samples (+) and non-crosslinked controls (-). 
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Highlights 
- protein-mRNA complexes are stabilized by chemical or photocrosslinking 
- isolation of crosslinked protein-RNA complexes by oligo(dT) affinity purification 
- mRNA interactome capture identifies mRNA-binding proteins 
 
